In a patient aged 65 years or older who is behind on vaccinations, should the 20‑valent pneumococcal conjugate vaccine (PCV20) be given as the preferred pneumococcal vaccine?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 2, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Yes, give PCV20 (20-valent pneumococcal conjugate vaccine) to adults over 65 who are behind on their pneumococcal vaccines.

For any adult aged ≥65 years who has never received a pneumococcal vaccine or whose vaccination history is unknown, administer a single dose of PCV20 as the preferred option 1. This represents the most straightforward and effective approach based on current ACIP guidelines from 2023.

Why PCV20 is Preferred

The 2023 ACIP guidelines provide two acceptable options for vaccine-naïve older adults:

  • Option A: Single dose of PCV20 alone
  • Option B: PCV15 followed by PPSV23 after ≥1 year interval

However, PCV20 alone is superior for several key reasons:

Practical Advantages

  • Single-dose regimen eliminates the need for a return visit, dramatically improving completion rates
  • Broader serotype coverage (20 serotypes vs. 15 in PCV15) without requiring a second vaccine
  • Immunologic superiority of conjugate vaccines over polysaccharide vaccines, providing better immune memory 1

Clinical Evidence

PCV20 has demonstrated robust safety and immunogenicity in adults ≥65 years in Phase III trials 2. The vaccine covers approximately 30% of invasive pneumococcal disease cases in adults through its seven additional serotypes beyond PCV13 3.

Cost-Effectiveness

Economic modeling shows PCV20 is cost-saving compared to no vaccination in the age-based 65+ population, meaning it both improves health outcomes AND reduces overall healthcare costs 4. When compared to the PCV15/PPSV23 sequence, PCV20 ranges from cost-saving to highly cost-effective across multiple analyses 4, 5, 6.

Practical Implementation

If the patient has truly never received any pneumococcal vaccine:

  • Give PCV20 immediately
  • No follow-up pneumococcal vaccine needed
  • Document as complete series 1

Common pitfall to avoid: Don't assume older adults have received vaccines just because they "should have." Many are genuinely vaccine-naïve, and the simplified single-dose PCV20 strategy was designed specifically for this scenario 7.

Special Considerations

The recommendation is even stronger if the patient has:

  • Immunocompromising conditions
  • Chronic medical conditions (diabetes, heart disease, lung disease, smoking)
  • Limited healthcare access or adherence concerns

In these populations, the single-dose simplicity of PCV20 becomes even more valuable, as the two-dose PCV15/PPSV23 series has poor completion rates in real-world practice 6.

Recent Updates

Note that as of October 2024, ACIP expanded recommendations to include all adults ≥50 years (not just ≥65), and added PCV21 as another single-dose option alongside PCV20 8, 3. This reflects growing recognition that pneumococcal vaccination should start earlier and be simpler to implement.

The bottom line: For a vaccine-naïve adult over 65, give PCV20 now as a single dose and consider them complete 1.

References

Related Questions

What are the recommended dosing, schedule, contraindications, and alternative regimen for PCV20 (20‑valent pneumococcal conjugate vaccine) in adults?
What are the current recommendations for pneumococcal vaccination, including the available conjugate pneumococcal vaccines (PCV20, PCV15) and polysaccharide pneumococcal vaccine (PPSV23) for adults and the 13‑valent conjugate pneumococcal vaccine (PCV13) for children?
In a 73‑year‑old patient with unknown prior pneumococcal vaccination status, is there any contraindication to administering a second dose of pneumococcal conjugate vaccine 20‑valent (PCV20)?
If the 23‑valent pneumococcal polysaccharide vaccine (PPSV23) was administered on a specific date, does the patient still need the 15‑valent pneumococcal conjugate vaccine (PCV15)?
Should a 70-year-old patient with diabetes receive the 20-valent pneumococcal conjugate vaccine (PCV20) or the 23-valent pneumococcal polysaccharide vaccine (PPSV23) given that his last pneumococcal vaccine was PPSV23 six years ago?
Can the absorption of levothyroxine be affected by GLP-1 analogues?
Can Buerger's disease (thromboangiitis obliterans) cause cutaneous vasculitis?
In a Canadian primary‑care setting, how should an adult patient with an elevated serum alpha‑fetoprotein (AFP) be evaluated and managed?
In a patient with MRSA mastitis, how is the lower extremity edema associated with the infection?
In a 27‑year‑old man with brief spontaneous vertigo episodes, negative Dix‑Hallpike and Romberg tests, and normal emergency department labs and cardiac work‑up, what additional bedside examination should be performed in clinic?
Which antidepressant medications are safe to use for a patient with depression who also has Roemheld syndrome?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.